» Articles » PMID: 34155064

Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics

Abstract

Background: Hispanics in South Texas have high rates of hepatocellular carcinoma (HCC) and nonalcoholic fatty liver disease (NAFLD). Liver fibrosis severity is the strongest predictive factor of NAFLD progression to HCC. We examined the association between free fatty acids (FA) and advanced liver fibrosis or HCC in this population.

Methods: We quantified 45 FAs in plasma of 116 subjects of the Cameron County Hispanic Cohort, 15 Hispanics with HCC, and 56 first/second-degree relatives of Hispanics with HCC. Liver fibrosis was assessed by FibroScan.

Results: Advanced liver fibrosis was significantly associated with low expression of very long chain (VLC) saturated FAs (SFA), odd chain SFAs, and VLC n-3 polyunsaturated FAs [PUFA; AOR; 95% confidence interval (CI), 10.4 (3.7-29.6); < 0.001; 5.7 (2.2-15.2); < 0.001; and 3.7 (1.5-9.3); = 0.005]. VLC n3-PUFAs significantly improved the performance of the noninvasive markers for advanced fibrosis - APRI, FIB-4, and NFS. Plasma concentrations of VLC SFAs and VLC n-3 PUFAs were further reduced in patients with HCC. Low concentrations of these FAs were also observed in relatives of patients with HCC and in subjects with the rs738409 homozygous genotype.

Conclusions: Low plasma concentrations of VLC n-3 PUFAs and VLC SFAs were strongly associated with advanced liver fibrosis and HCC in this population. Genetic factors were associated with low concentrations of these FAs as well.

Impact: These results have implications in identifying those at risk for liver fibrosis progression to HCC and in screening this population for advanced fibrosis. They also prompt the evaluation of VLC n-3 PUFA or VLC SFA supplementation to prevent cirrhosis and HCC.

Citing Articles

Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.

Liu Z, Huang H, Xie J, Xu Y, Xu C Nat Commun. 2024; 15(1):3707.

PMID: 38697980 PMC: 11065883. DOI: 10.1038/s41467-024-47960-8.


Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds.

Venn-Watson S, Schork N Nutrients. 2023; 15(21).

PMID: 37960259 PMC: 10649853. DOI: 10.3390/nu15214607.


Fatty Acids and Bilirubin as Intrinsic Autofluorescence Serum Biomarkers of Drug Action in a Rat Model of Liver Ischemia and Reperfusion.

Croce A, Ferrigno A, Palladini G, Mannucci B, Vairetti M, Di Pasqua L Molecules. 2023; 28(9).

PMID: 37175228 PMC: 10180479. DOI: 10.3390/molecules28093818.


Fatty Acid Profile and Genetic Variants of Proteins Involved in Fatty Acid Metabolism Could Be Considered as Disease Predictor.

Chaaba R, Bouaziz A, Ben Amor A, Mnif W, Hammami M, Mehri S Diagnostics (Basel). 2023; 13(5).

PMID: 36900123 PMC: 10001328. DOI: 10.3390/diagnostics13050979.


Prevalence and factors associated with liver fibrosis among first-degree relatives of Mexican Americans with hepatocellular carcinoma.

Sharpton S, Shan K, Bettencourt R, Lee M, McCormick J, Fisher-Hoch S Aliment Pharmacol Ther. 2023; 57(4):378-386.

PMID: 36628455 PMC: 10792515. DOI: 10.1111/apt.17384.


References
1.
Fisher-Hoch S, Vatcheva K, Rahbar M, McCormick J . Undiagnosed Diabetes and Pre-Diabetes in Health Disparities. PLoS One. 2015; 10(7):e0133135. PMC: 4505949. DOI: 10.1371/journal.pone.0133135. View

2.
Singal A, Manjunath H, Yopp A, Beg M, Marrero J, Gopal P . The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014; 109(3):325-34. PMC: 5610907. DOI: 10.1038/ajg.2013.476. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Papandreou C, Sala-Vila A, Galie S, Muralidharan J, Estruch R, Fito M . Association Between Fatty Acids of Blood Cell Membranes and Incidence of Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2019; 39(4):819-825. DOI: 10.1161/ATVBAHA.118.312073. View

5.
Karlas T, Petroff D, Sasso M, Fan J, Mi Y, de Ledinghen V . Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66(5):1022-1030. DOI: 10.1016/j.jhep.2016.12.022. View